VERACITY – A decade of trust and clinical excellence
VERACITY is a new generation test that provides doctors with reliable information and patients with peace of mind.
VERACITY was one of the first non-invasive prenatal tests to enter the international market. Over the past decade, it has become available in more than 60 countries and has set a new standard for clinical value, reliability, and accuracy.
Through continuous scientific work and innovative technologies, Medicover Genetics has updated the microdeletion panel, further expanding the clinical capabilities of the VERACITY and VERAgene NIPT tests.
From November 2025, the VERACITY and VERAgene tests will include common and clinically important microdeletion syndromes: Prader–Willi, Angelman, and Cri-du-chat.
VERACITY and VERAgene NIPT tests can now be performed from the 9th week of pregnancy, allowing for reliable results and informed decisions to be made more quickly.
VERACITY's unique targeted-capture enrichment technology focuses on the study of targeted, clinically important genomic regions, ensuring high analytical accuracy and consistent results across pregnancy variants.
Medicover Genetics continues to invest in science and innovation to make high-quality genetic research available to more people in more countries!
Follow our social pages and learn more
